Literature DB >> 28318717

[Individualized management of patients with exudative AMD, IOI protocol: Injection-observational-individualization].

O Semoun1, S Y Cohen2, M Srour1, C Creuzot-Garchet3, H Oubraham-Mebroukine4, L Kodjikian5, F Devin6, E H Souied7.   

Abstract

Wet macular degeneration remains a major cause of visual impairment in people over 55years. Through a group of experts belonging to the Federation France Macula, we review the treatment of wet AMD and provide recommendation with a 3 phases protocol called IOI.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  AMD; DMLA; Medical care; Prise en charge; Protocoles thérapeutiques; Therapeutic protocols

Mesh:

Year:  2017        PMID: 28318717     DOI: 10.1016/j.jfo.2016.12.003

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  1 in total

1.  Intravitreal anti-VEGF use in France: a cross-sectional and longitudinal Nationwide observational study.

Authors:  Sophie Billioti de Gage; Marion Bertrand; Sébastien Grimaldi; Mahmoud Zureik
Journal:  Acta Ophthalmol       Date:  2021-06-14       Impact factor: 3.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.